Kaken Pharmaceutical saw the highest growth of 0.99% in patent filings in April and 0.49% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Kaken Pharmaceutical’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Kaken Pharmaceutical has been focused on protecting inventions in Canada(CA) with one publication in Q2 2024
The Canada(CA) Patent Office dominates the patent grants with nearly 33% of grants. The World Intellectual Property Organization(WIPO), Canada(CA), European Patent Office(EPO), and Japan(JP) patent Office are among the top ten patent offices where Kaken Pharmaceutical is filings its patents. Among the top granted patent authorities, Kaken Pharmaceutical has 33% of its grants in Canada(CA), 33% in European Patent Office(EPO) and 33% in Japan(JP).
Roche could be the strongest competitor for Kaken Pharmaceutical
Patents related to addiction and rare diseases lead Kaken Pharmaceutical's portfolio
Kaken Pharmaceutical has the highest number of patents in addiction followed by, rare diseases. For addiction no patents were filed and 40% of patents were granted in Q2 2024.
Pain related patents lead Kaken Pharmaceutical portfolio followed by atopic dermatitis (atopic eczema)
Kaken Pharmaceutical has highest number of patents in pain followed by atopic dermatitis (atopic eczema).
For comprehensive analysis of Kaken Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

